Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
Nothing from your lists
Collegium Pharmaceutical, Inc · “On October 15, 2026, the Company and Grünenthal entered into a settlement agreement (the “Settlement Agreement”) to resolve all disputes and claims between the parties, including the Nucynta Litigation.”¶1
Integra Lifesciences Holdings Corp · “On October 19, 2026, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer (the “Credit Agreement”).”¶1
Mobix Labs, Inc · “On October 14, 2026, Mobix Labs, Inc. (the “Company”) delivered written notice to Vision Aerial, Inc. (“Vision Aerial”)”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
On October 19, 2026, Prysmian S.p.A. completed its acquisition of Atkore Inc. through a merger in which Merger Sub merged with and into the Company, which survives as a wholly owned subsidiary of Buyer.¶1¶2
Each share of Company Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive $95.00 in cash, without interest.¶3
A change in control of the Company occurred at the Effective Time, and the aggregate cash Merger Consideration payable by Buyer is approximately $3.3 billion, funded by equity and debt financing.¶4
The Company terminated its credit facilities, repaid all obligations under them, and redeemed all $400 million in aggregate principal amount of its 4.25% Senior Notes due 2031 at 102.125% of principal.
Management identified errors in the unaudited condensed financial statements in the Q2 10-Q for the quarter ended June 30, 2026, affecting private placement unit proceeds, unit counts, redeemable shares and warrants.¶1
On October 14, 2026, the audit committee concluded the previously issued financial statements should be restated and no longer relied upon, with Amendment No. 1 to be filed October 16, 2026.¶2
Anna Brunelle resigned from the Board and from its audit and compensation committees, effective October 13, 2026.¶3
On October 14, 2026, the Board appointed Christopher Valentine to the audit committee, filling the vacancy left by Ms. Brunelle.¶4
Tom Watson resigned as Chief Operating Officer of the Company, effective October 14, 2026.¶5
The Phase 3 LUCIA study of DURAVYU in wet AMD did not meet its primary endpoint of non-inferiority, despite vision improvements and meeting key secondary endpoints.¶1
The Board approved a Prioritization plan to conclude the pivotal Phase 3 wet AMD trials early and reduce the workforce by approximately 53%.¶2
The Company estimates aggregate charges of approximately $9 million related to employee separation benefits, with a majority recognized in the fourth quarter of 2026.¶3
The Company expects estimated annualized savings of approximately $30 million and estimates approximately $118 million in cash, cash equivalents, and short-term investments as of September 30, 2026.¶4¶5
Globaltek Ventures, Inc. engaged Bansal & Co LLP as its independent registered public accounting firm to review interim financial statements for the six months ended June 30, 2026.¶1
The engagement terminates upon the completion of the review.¶1
The filing states that, for the fiscal years ended December 31, 2025 and 2024 and the interim period through October 15, 2026, the Company did not consult Bansal on accounting or auditing matters, except as discussed in the October 15 Form 8-K.¶2
On October 16, 2026, Teamshares Continuity Holdings LLC entered into a Credit Agreement with the Company, Teamshares LLC, and Sound Point Agency LLC as agent, providing a senior secured term loan facility of $130.0 million.¶1¶2
The Borrower used the Term Loan proceeds, cash on hand and released restricted cash to repay in full the Existing Credit Agreement for an aggregate payoff of approximately $152.8 million, including $150.0 million of principal and $2.8 million of accrued interest.¶3¶4
The Term Loan bears interest at one-month Term SOFR, subject to a floor of 3.00%, plus 9.50% per annum, payable monthly in cash, and may be prepaid without premium or penalty on three business days' notice.¶5
The Company may not pay dividends or repurchase its equity or rights to acquire its equity without the Agent's consent, subject to certain exceptions, while the Credit Agreement is outstanding.¶6¶7¶8
On October 15, 2026, Collegium Pharmaceutical and Grünenthal GmbH entered into a settlement agreement to resolve all disputes and claims, including the Nucynta Litigation.¶1
The parties agreed to terminate the Grünenthal License in its entirety and the Consent Agreement with respect to the Territory, effective October 15, 2026 after the Company paid $17,000,000.¶1
All Company royalty obligations under the Grünenthal License have been fully and finally discharged, and no further royalties will be due under it.¶1
Grünenthal assigned certain patents related to the Nucynta Products to the Company and filed a motion to dismiss the Nucynta Litigation.¶1
On October 19, 2026, Integra completed a private unregistered offering of $450 million aggregate principal amount of 9.500% Senior Secured Notes due 2033, which bear interest payable semi-annually.¶1¶2
The amended and restated Credit Agreement makes up to $1.65 billion available through a $600 million senior secured revolving facility, a $600 million term loan A and a $450 million term loan B.¶3
Integra used proceeds of the new borrowings and Notes offering to repay in full all loans under its Existing Credit Agreement dated March 24, 2023, and the revolving commitments were terminated, with no early termination penalties.¶4
Integra stated it used the net proceeds, together with borrowings under the Credit Facility, to refinance its existing credit facility and pay fees and expenses.¶5
On October 14, 2026, Mobix Labs delivered written notice to Vision Aerial terminating the Agreement and Plan of Merger dated July 24, 2026, pursuant to Section 8.1(c), following the expiration of the contractual termination date.¶1¶2
The Merger Agreement was previously disclosed in the Company's Current Report on Form 8-K filed on July 29, 2026.¶2
The termination followed delays in completing certain due diligence and financial reporting matters, including receipt of financial and accounting information necessary to complete the audit process.¶3
The transaction was not consummated within the contemplated timeframe.¶3
The termination was amicable, and the Company remains open to exploring potential opportunities with Vision Aerial in the future.¶4
On October 15, 2026, Dairyland USA Corporation and Chefs' Warehouse Parent, LLC entered into a new credit agreement with a group of lenders, and borrowed the full $675,000,000 of senior secured term loans maturing October 15, 2033.¶2¶3¶1
The Borrowers repaid in full the Prior Term Loan Credit Agreement, including accrued interest, for approximately $244.7 million, and the prior agreement was terminated.¶4
The Company entered into a ninth amendment to its asset based revolving credit agreement, which increases the letter of credit sublimit from $50,000,000 to $75,000,000.¶5
Holders of approximately $287.2 million aggregate principal amount of the 2.375% Convertible Senior Notes due 2028 elected to convert, and on October 15, 2026 the Company delivered 2,671,056 shares of common stock to those holders.¶6
On the Redemption Date, the Company redeemed all approximately $341,000 aggregate principal amount of Notes not previously surrendered for conversion, at 100% of principal plus accrued and unpaid interest.¶7
On October 16, 2026, Vivos completed its acquisition of at least 11% of SOD Sciences' fully diluted capital stock and an undivided 50% co-ownership interest in SOD's pseudohypoxia test, issuing 12,000 Series C Preferred shares with an aggregate stated value of $12,000,000 and no cash paid.¶2¶3
The Series C Preferred converts at $0.15 per share into up to 80,000,000 shares of common stock, and until stockholder approval is obtained no more than 6,718,517 shares may be issued upon conversion.¶4
The Series C Preferred was issued under the Section 4(a)(2) exemption from registration, with SOD representing it acquired the shares for investment, and no underwriter or placement agent was involved.¶5
The Company believes that, giving effect to the Closing, its stockholders' equity exceeds the $2,500,000 minimum of Nasdaq Listing Rule 5550(b)(1), and it currently expects the Closing to increase stockholders' equity by more than $10 million.¶6¶7
On October 14, 2026, Cambium Networks, Ltd (in administration) sold its remaining business and group subsidiaries as a going concern to Univastu UK Limited under a Business Sale Agreement.¶2
The purchase price was approximately US$5.1 million in cash, of which approximately US$0.3 million had previously been paid as a non-refundable deposit, with the balance paid at completion.¶3
The Company does not expect to retain any of the net proceeds, which are expected to be applied to repayment of amounts outstanding under the Credit Facility, and does not expect proceeds to be available for distribution to shareholders.¶4
Following the Sale, the Company no longer has any operating subsidiaries, and it expects CNL to proceed into liquidation and the Company to be dissolved and wound up under Cayman Islands law.¶5
On October 15, 2026, SVC sold three hotels for an aggregate sales price of $19.0 million, excluding closing costs.¶1
The sale was made under a purchase and sale agreement SVC previously entered, and the three hotels constitute a significant disposition for Item 2.01 purposes.¶1
Pro forma financial information is not included because the disposed assets do not constitute a significant portion of a business under Article 11 of Regulation S-X.¶1
On October 16, 2026, the Company completed the sale of its Durango property to American Heritage Legacies, LLC for $6.6 million, and the lease commenced; the buyer is controlled by the family of the Interim CEO.¶1¶2
On October 16, 2026, the Company entered into a $2.0 million term loan with Alpine Bank, fully funded that day for working capital, maturing October 16, 2028.¶3¶4
Net sale proceeds were used to repay approximately $6.6 million of principal and accrued interest on notes, and the Company incurred prepayment penalties and related costs of $0.3 million.¶5¶6
Total revenue was $6.7 million for the second quarter of fiscal 2027, compared to $6.8 million a year earlier, and the net loss was $1.3 million or $(0.14) per share.¶7¶8
The Board formed a strategic committee that, with its advisors, is exploring strategic alternatives, including a possible sale, merger, or going-private transaction, and has received expressions of interest from third parties.¶9¶10¶11
